Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
Nicolò De Gennaro(University of Bari Aldo Moro), Annalisa Saracino(University of Bari Aldo Moro), Gioacchino Angarano(University of Bari Aldo Moro), Lucia Diella(Humanitas University), Laura Monno(University of Bari Aldo Moro), Michele Stanislaw Milella(University of Verona)
Cited by 14
Related Papers
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
Incidence of long COVID-19 in people with previous SARS-Cov2 infection: a systematic review and meta-analysis of 120,970 patients
|Internal and Emergency Medicine|2022|113